BR112013025197A2 - métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer - Google Patents

métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer

Info

Publication number
BR112013025197A2
BR112013025197A2 BR112013025197A BR112013025197A BR112013025197A2 BR 112013025197 A2 BR112013025197 A2 BR 112013025197A2 BR 112013025197 A BR112013025197 A BR 112013025197A BR 112013025197 A BR112013025197 A BR 112013025197A BR 112013025197 A2 BR112013025197 A2 BR 112013025197A2
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
effectiveness
methods
evaluating
Prior art date
Application number
BR112013025197A
Other languages
English (en)
Inventor
Backes Larry
R Relkin Norman
Schiff Richard
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112013025197A2 publication Critical patent/BR112013025197A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

métodos para tratar doença de alzheimer e para avaliar a eficácia de uma terapia destinada a tratar doença de alzheimer a presente invenção se refere ao uso do nível de certas citocinas em um sangue de paciente como uma medida objetiva com o propósito de avaliar progressão de doença em pacientes que sofrem a doença de alzheimer e com o propósito de determinar efetividade terapêutica de um regime de tratamento. são providos métodos para tratar doença de alzheimer e monitorar a efetividade terapêutica. preferivelmente, o agente terapêutico é uma composição de imunoglobina intravenosa (ivig).
BR112013025197A 2011-04-01 2012-03-30 métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer BR112013025197A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470819P 2011-04-01 2011-04-01
PCT/US2012/031667 WO2012135752A1 (en) 2011-04-01 2012-03-30 Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112013025197A2 true BR112013025197A2 (pt) 2019-09-24

Family

ID=46208748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025197A BR112013025197A2 (pt) 2011-04-01 2012-03-30 métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer

Country Status (12)

Country Link
US (1) US20120251524A1 (pt)
EP (1) EP2694978A1 (pt)
JP (1) JP2014513284A (pt)
KR (1) KR20130143659A (pt)
CN (1) CN103547924A (pt)
AR (1) AR085837A1 (pt)
AU (1) AU2012236137A1 (pt)
BR (1) BR112013025197A2 (pt)
CA (1) CA2831863A1 (pt)
MX (1) MX2013011325A (pt)
TW (1) TW201250247A (pt)
WO (1) WO2012135752A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AU2014262890B2 (en) * 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
CN105353135A (zh) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 阿尔茨海默病标志物的用途
CA3194052A1 (en) * 2020-09-08 2022-03-17 Longeveron, Inc. Treatment of alzheimer's disease with allogeneic mesenchymal stem cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
ES2411455T3 (es) * 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
BRPI0606991A2 (pt) * 2005-02-14 2009-08-18 Wyeth Corp métodos para triar compostos de teste capazes de antagonizar a sinalização de il-17f, para diagnosticar um distúrbio relacionado com a sinalização aumentada de il-17f em um indivìduo, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-21, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-23, para purificar a proteìna il-17a natural, e para isolar heterodìmeros de il-17 a/il-17f substancialmente isentos de homodìmeros de il-17a e homodìmeros de il-17f, uso de uma quantidade terapeuticamente eficaz de um antagonista da sinalização de il-17f, composição farmacêutica, adjuvante de vacina, anticorpo isolado, proteìnas il-17f e il-17a isoladas, e, heterodìmero de il-17a/il-17f
WO2007059135A2 (en) * 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2009021708A2 (en) * 2007-08-13 2009-02-19 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110250206A1 (en) * 2010-02-11 2011-10-13 Axtell Robert C Markers for determination of patient responsiveness
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Also Published As

Publication number Publication date
AU2012236137A1 (en) 2013-05-02
US20120251524A1 (en) 2012-10-04
KR20130143659A (ko) 2013-12-31
EP2694978A1 (en) 2014-02-12
CA2831863A1 (en) 2012-10-04
JP2014513284A (ja) 2014-05-29
MX2013011325A (es) 2014-07-09
AR085837A1 (es) 2013-10-30
WO2012135752A1 (en) 2012-10-04
TW201250247A (en) 2012-12-16
CN103547924A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
CO6561786A2 (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
IN2015DN00450A (pt)
MX2018002000A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CL2023003003A1 (es) Tratamiento y diagnóstico de trastornos inflamatorios
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
BR112015004653A2 (pt) método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.